Retatrutide Reconstitution Shelf Life
There is no available information on the shelf life of retatrutide after reconstitution in the provided evidence, as retatrutide is currently an investigational agent without FDA approval or published drug labeling that addresses storage and stability after reconstitution. 1
Current Development Status
Retatrutide is a triple-hormone receptor agonist (GLP-1, GIP, and glucagon receptors) that remains in clinical development for obesity and type 2 diabetes. 2, 3, 4
Phase 2 trials have demonstrated substantial weight loss (up to 24.2% at 48 weeks) and significant HbA1c reductions (up to 2.02% at 24 weeks) in adults with type 2 diabetes and obesity. 3, 4
The drug is administered as a once-weekly subcutaneous injection based on pharmacokinetic data from phase 1b trials. 5
Clinical Context
Since retatrutide has not received FDA approval, there are no official prescribing guidelines, storage requirements, or reconstitution instructions available. 1
Current clinical trials use pre-filled formulations with dosing ranging from 1 mg to 12 mg weekly, but specific pharmaceutical preparation details have not been published. 3, 4
The safety profile shows predominantly gastrointestinal adverse events (nausea, diarrhea, vomiting) consistent with other GLP-1 receptor agonists, but no published data addresses post-reconstitution stability. 3, 4
Practical Considerations
For any compounded or reconstituted formulation of retatrutide in clinical practice, you must follow standard pharmaceutical compounding guidelines for peptide medications until official FDA labeling becomes available.
Similar GLP-1 receptor agonists like semaglutide and dulaglutide have specific manufacturer guidelines for storage that typically require refrigeration and limited shelf life after first use. 6
Without official stability data, any reconstituted retatrutide should be treated with maximum caution regarding sterility, temperature control, and expiration dating per USP <797> compounding standards.
Contact the manufacturer (Eli Lilly and Company) directly or await FDA approval and official prescribing information before using any reconstituted formulation of retatrutide in clinical practice. 3, 4